Long‐Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke

  title={Long‐Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke},
  author={Jeffrey L. Saver and John D. Carroll and David E Thaler and Richard W Smalling and Lee A. Macdonald and David S Marks and David L. Tirschwell},
  journal={The New England Journal of Medicine},
BACKGROUND Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown. METHODS In a multicenter, randomized, open‐label trial, with blinded adjudication of end‐point events, we randomly assigned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PFO (PFO closure group) or to receive medical therapy alone (aspirin… 

Figures and Tables from this paper

Long-term efficacy after closure of patent foramen ovale for ischemic neurological events in young adults

It is indicated that PFO closure is the best treatment strategy for younger patients under the age of 55 for prevention of recurrent ischemic neurological events.

Patent Foramen Ovale Closure in the Setting of Cryptogenic Stroke: A Meta-Analysis of Five Randomized Trials.

  • Lohit GargA. Haleem B. Kluck
  • Medicine, Psychology
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2018

The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke

The long-term results of the RESPECT trial led to the Food and Drug Administration approval of the AMPLATZER PFO Occluder for a secondary prevention indication and translates the results and methods from investigative trials into clinical practice.

Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke

An updated meta-analysis of trials comparing transcatheter PFO closure with medical therapy alone for prevention of recurrent stroke in patients with cryptogenic stroke and PFO was done.

Closure or medical therapy of patent foramen ovale in cryptogenic stroke: prospective case series

In this real-world study, IS recurrence rate in ‘PFO-closure’ high-risk PFO patients ≤60 years was comparable to that observed in recent RCT, and MTA seems the appropriate treatment for low- risk PFO.

Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events

PFO closure might have a role in secondary CVE prevention of patients with PFO and cryptogenic stroke, however, it is associated with an increased incidence of new-onset atrial fibrillation/AFL especially within 1 month.

Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials

PFO-C after cryptogenic ischemic stroke is safe and effective to reduce the risk of recurrent stroke and recurrent stroke + TIA, albeit with an increased risk for NOAF.



Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.

There was no significant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic ischemic stroke, however, closure was superior to medical therapy alone in the prespecified per-protocol and as-treated analyses, with a low rate of associated risks.

Closure or medical therapy for cryptogenic stroke with patent foramen ovale.

In patients with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a greater benefit than medical therapy alone for the prevention of recurrent stroke orTIA.

Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials.

Percutaneous closure of patent foramen ovale in cryptogenic embolism.

Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant reduction in the risk of recurrent embolic events or death as compared with medical therapy.

Long-Term Propensity Score–Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical Embolism

Percutaneous PFO closure was more effective than medical treatment for the secondary prevention of recurrent cerebrovascular events among patients with PFO-related transient ischemic attack or stroke.

Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.

PFO closure with AMP appears superior to medical therapy in preventing strokes in patients with cryptogenic embolism, but the effectiveness of PFO closure depends on the device used.

Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.

Although procedural complications and long-term neurological event rates are low regardless of the device used, the recurrent neurological event rate was significantly lower after Amplatzer than after CardioSEAL-STARflex or Helex implantation.

Very long-term follow-up after percutaneous closure of patent foramen ovale.

Long-term follow-up following percutaneous PFO closure for presumed paradoxical embolism reveals very low recurrence rates.

Patent Foramen Ovale in Cryptogenic Stroke: Incidental or Pathogenic?

In patients with otherwise CS, approximately one third of discovered PFOs are likely to be incidental and hence not benefit from closure, suggesting the importance of patient selection in therapeutic decision-making.

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke; surgery resulted in fewer major vascular complications and less paravalvular aorta regurgitation.